|
Sep 30
|
Nurix Therapeutics Announces Presentations at Discovery on Target Conference
|
|
Jul 25
|
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
|
|
Jun 24
|
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
|
|
Jun 20
|
Insider Sale: CFO Houte Van Sells 20,000 Shares of Nurix Therapeutics Inc (NRIX)
|
|
Jun 19
|
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
|
|
Jun 17
|
Nurix Therapeutics, With 345% Run, Posts A 'Clear Win' In Leukemia Treatment
|
|
Jun 16
|
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
|
|
May 14
|
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
|
|
May 7
|
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
|
|
Apr 16
|
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
|
|
Apr 15
|
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
|
|
Apr 12
|
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
|
|
Apr 11
|
Nurix Therapeutics Announces Proposed Public Offering
|
|
Apr 11
|
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
|
|
Apr 10
|
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
|
|
Apr 10
|
Nurix Therapeutics Inc (NRIX) Misses Earnings Predictions But Shows Revenue Growth in Q1 Fiscal 2024
|
|
Apr 10
|
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
|
|
Apr 10
|
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
|
|
Apr 9
|
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
|
|
Apr 9
|
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
|